Galilee Medical Center, abbreviated GMC, is a hospital located in the coastal city of Nahariya and is the second largest hospital in northern Israel. It was established in 1956.

There are 722 beds in Galilee Medical Center.

During the past decade, Galilee Medical Center conducted 117 clinical trials. In the 10-year time frame, 117 clinical trials started and 43 clinical trials were completed, i.e. on average, 36.8% percent of trials that started reached the finish line to date. In the past 5 years, 55 clinical trials started and 32 clinical trials were completed. i.e. 58.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Galilee Medical Center" #1 sponsor was "Western Galilee Hospital-Nahariya" with 49 trials, followed by "Bayer" with 11 trials sponsored, "Janssen Research & Development, LLC" with 9 trials sponsored, "Celgene" with 8 trials sponsored and "Hoffmann-La Roche" with 8 trials sponsored. Other sponsors include 87 different institutions and companies that sponsored additional 65 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Galilee Medical Center" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials as a collaborator and "Medidata Solutions" with 2 trials as a collaborator. Other collaborators include 33 different institutions and companies that were collaborators in the rest 42 trials.

According to Clinical.Site data, the most researched conditions in "Galilee Medical Center" are "Ulcerative Colitis" (9 trials), "Crohn's Disease" (6 trials), "Colitis, Ulcerative" (4 trials), "Acute Myocardial Infarction" (3 trials) and "Atrial Fibrillation" (3 trials). Many other conditions were trialed in "Galilee Medical Center" in a lesser frequency.

Most popular intervention types in "Galilee Medical Center" are "Drug" (107 trials), "Other" (28 trials), "Device" (21 trials), "Procedure" (14 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (51 trials), "Etrasimod" (5 trials), "Apixaban" (4 trials), "Ontamalimab" (4 trials) and "Tirzepatide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Galilee Medical Center" are 138 trials for "All" genders and 38 trials for "Female" genders.

Currently, there are 56 active trials in "Galilee Medical Center". 3 are not yet recruiting, 31 are recruiting, 21 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 78 completed trials in Galilee Medical Center, 1 suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Galilee Medical Center, 5 "Phase 1" clinical trials were conducted, 38 "Phase 2" clinical trials and 73 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 31 trials that are defined as “Not Applicable".

Galilee Medical Center has several departments that took part in Clinical trials: "Galilee Medical Center Department of Internal Medicine A" - 5 trials, "Nahariya Hospital; Oncology" - 3 trials, "Department of Obstetrics and Gynecology" - 3 trials, "Galilee Medical Center, Cardiology Department" - 2 trials